Usefulness of N-Terminal Pro-B-Type natriuretic peptide increase as a marker for cardiac arrhythmia in patients with syncope

Giorgio Costantino, Monica Solbiati, Giovanni Casazza, Mattia Bonzi, Tarcisio Vago, Nicola Montano, Daniel McDermott, James Quinn, Raffaello Furlan

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

B-type natriuretic peptides (BNPs) have been investigated as biomarkers for risk stratification of patients with syncope. Their concentration can be influenced by age and co-morbidities. In the present study, we compared the change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels within 6 hours in patients with vasovagal and arrhythmic syncope to determine whether this change can predict arrhythmic syncope. Using a case-control design, 33 patients were enrolled. Of the 33 patients, 18 with arrhythmic syncope, as they underwent controlled ventricular tachycardia or ventricular fibrillation (VF) during device safety testing of an implantable cardioverter defibrillator implantation or battery replacement, were compared with 15 patients, who during a tilt-table test were diagnosed with vasovagal syncope (VS). For each patient, a blood sample for NT-proBNP evaluation was collected at baseline and 6 hours after the episode of ventricular tachycardia, VF, or VS. We calculated the percentage of increase in the 6-hour NT-proBNP concentration between the 2 groups using nonparametric techniques. We also calculated the area under a receiver operating characteristic curve with the 95% confidence intervals. The 6-hour change in the NT-proBNP concentrations between patients who had had an episode of ventricular tachycardia or VF and patients with VS was significantly different, with a median increase of 32% in the ventricular tachycardia or VF group versus 5% in the VS group (p

Original languageEnglish
Pages (from-to)98-102
Number of pages5
JournalThe American Journal of Cardiology
Volume113
Issue number1
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Brain Natriuretic Peptide
Syncope
Vasovagal Syncope
Cardiac Arrhythmias
Ventricular Fibrillation
Ventricular Tachycardia
Tilt-Table Test
Equipment Safety
Implantable Defibrillators
ROC Curve
Biomarkers
Confidence Intervals
Morbidity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Usefulness of N-Terminal Pro-B-Type natriuretic peptide increase as a marker for cardiac arrhythmia in patients with syncope. / Costantino, Giorgio; Solbiati, Monica; Casazza, Giovanni; Bonzi, Mattia; Vago, Tarcisio; Montano, Nicola; McDermott, Daniel; Quinn, James; Furlan, Raffaello.

In: The American Journal of Cardiology, Vol. 113, No. 1, 01.01.2014, p. 98-102.

Research output: Contribution to journalArticle

Costantino, Giorgio ; Solbiati, Monica ; Casazza, Giovanni ; Bonzi, Mattia ; Vago, Tarcisio ; Montano, Nicola ; McDermott, Daniel ; Quinn, James ; Furlan, Raffaello. / Usefulness of N-Terminal Pro-B-Type natriuretic peptide increase as a marker for cardiac arrhythmia in patients with syncope. In: The American Journal of Cardiology. 2014 ; Vol. 113, No. 1. pp. 98-102.
@article{48b6a1f283004de0bcd2f28b9607c3e9,
title = "Usefulness of N-Terminal Pro-B-Type natriuretic peptide increase as a marker for cardiac arrhythmia in patients with syncope",
abstract = "B-type natriuretic peptides (BNPs) have been investigated as biomarkers for risk stratification of patients with syncope. Their concentration can be influenced by age and co-morbidities. In the present study, we compared the change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels within 6 hours in patients with vasovagal and arrhythmic syncope to determine whether this change can predict arrhythmic syncope. Using a case-control design, 33 patients were enrolled. Of the 33 patients, 18 with arrhythmic syncope, as they underwent controlled ventricular tachycardia or ventricular fibrillation (VF) during device safety testing of an implantable cardioverter defibrillator implantation or battery replacement, were compared with 15 patients, who during a tilt-table test were diagnosed with vasovagal syncope (VS). For each patient, a blood sample for NT-proBNP evaluation was collected at baseline and 6 hours after the episode of ventricular tachycardia, VF, or VS. We calculated the percentage of increase in the 6-hour NT-proBNP concentration between the 2 groups using nonparametric techniques. We also calculated the area under a receiver operating characteristic curve with the 95{\%} confidence intervals. The 6-hour change in the NT-proBNP concentrations between patients who had had an episode of ventricular tachycardia or VF and patients with VS was significantly different, with a median increase of 32{\%} in the ventricular tachycardia or VF group versus 5{\%} in the VS group (p",
author = "Giorgio Costantino and Monica Solbiati and Giovanni Casazza and Mattia Bonzi and Tarcisio Vago and Nicola Montano and Daniel McDermott and James Quinn and Raffaello Furlan",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.amjcard.2013.08.044",
language = "English",
volume = "113",
pages = "98--102",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Usefulness of N-Terminal Pro-B-Type natriuretic peptide increase as a marker for cardiac arrhythmia in patients with syncope

AU - Costantino, Giorgio

AU - Solbiati, Monica

AU - Casazza, Giovanni

AU - Bonzi, Mattia

AU - Vago, Tarcisio

AU - Montano, Nicola

AU - McDermott, Daniel

AU - Quinn, James

AU - Furlan, Raffaello

PY - 2014/1/1

Y1 - 2014/1/1

N2 - B-type natriuretic peptides (BNPs) have been investigated as biomarkers for risk stratification of patients with syncope. Their concentration can be influenced by age and co-morbidities. In the present study, we compared the change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels within 6 hours in patients with vasovagal and arrhythmic syncope to determine whether this change can predict arrhythmic syncope. Using a case-control design, 33 patients were enrolled. Of the 33 patients, 18 with arrhythmic syncope, as they underwent controlled ventricular tachycardia or ventricular fibrillation (VF) during device safety testing of an implantable cardioverter defibrillator implantation or battery replacement, were compared with 15 patients, who during a tilt-table test were diagnosed with vasovagal syncope (VS). For each patient, a blood sample for NT-proBNP evaluation was collected at baseline and 6 hours after the episode of ventricular tachycardia, VF, or VS. We calculated the percentage of increase in the 6-hour NT-proBNP concentration between the 2 groups using nonparametric techniques. We also calculated the area under a receiver operating characteristic curve with the 95% confidence intervals. The 6-hour change in the NT-proBNP concentrations between patients who had had an episode of ventricular tachycardia or VF and patients with VS was significantly different, with a median increase of 32% in the ventricular tachycardia or VF group versus 5% in the VS group (p

AB - B-type natriuretic peptides (BNPs) have been investigated as biomarkers for risk stratification of patients with syncope. Their concentration can be influenced by age and co-morbidities. In the present study, we compared the change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels within 6 hours in patients with vasovagal and arrhythmic syncope to determine whether this change can predict arrhythmic syncope. Using a case-control design, 33 patients were enrolled. Of the 33 patients, 18 with arrhythmic syncope, as they underwent controlled ventricular tachycardia or ventricular fibrillation (VF) during device safety testing of an implantable cardioverter defibrillator implantation or battery replacement, were compared with 15 patients, who during a tilt-table test were diagnosed with vasovagal syncope (VS). For each patient, a blood sample for NT-proBNP evaluation was collected at baseline and 6 hours after the episode of ventricular tachycardia, VF, or VS. We calculated the percentage of increase in the 6-hour NT-proBNP concentration between the 2 groups using nonparametric techniques. We also calculated the area under a receiver operating characteristic curve with the 95% confidence intervals. The 6-hour change in the NT-proBNP concentrations between patients who had had an episode of ventricular tachycardia or VF and patients with VS was significantly different, with a median increase of 32% in the ventricular tachycardia or VF group versus 5% in the VS group (p

UR - http://www.scopus.com/inward/record.url?scp=84890438460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890438460&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2013.08.044

DO - 10.1016/j.amjcard.2013.08.044

M3 - Article

C2 - 24169011

AN - SCOPUS:84890438460

VL - 113

SP - 98

EP - 102

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 1

ER -